- Conditions
- Depression
- Interventions
- Scopolamine and naltrexone, placebo arm
- Drug
- Lead sponsor
- The Taub Group
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2377–2400
of 12,573
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Nemvaleukin Alfa, Pembrolizumab
- Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Interventions
- decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
- Drug · Biological · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Obesity, Childhood, Energy Density, Diet Quality
- Interventions
- family-based obesity prevention lifestyle intervention
- Behavioral
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support
- Drug · Behavioral
- Lead sponsor
- City University of New York
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Tampa, Florida + 3 more
- Conditions
- Cervical Cancer
- Interventions
- Cisplatin, Carboplatin, Paclitaxel, Trachelectomy
- Drug · Procedure
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
- Interventions
- Pembrolizumab, Lenvatinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Depression
- Interventions
- Ketamine, Cognitive Behavioral Therapy (CBT)
- Drug · Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Migraine With or Without Aura
- Interventions
- Low-Dose Naltrexone and Acetaminophen Combination, Placebo
- Drug
- Lead sponsor
- Allodynic Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Asthma
- Interventions
- fenoTRACK Device
- Device
- Lead sponsor
- Biometry Inc
- Industry
- Eligibility
- 5 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 13
- States / cities
- Stockton, California • Panama City, Florida • Columbus, Georgia + 10 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
- Conditions
- Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
- Interventions
- Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Aortic Stenosis
- Interventions
- Prehabilitation, Usual Care
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
- Drug · Radiation · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Colorectal Neoplasms
- Interventions
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, adjuvant therapy, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 14
- States / cities
- Tampa, Florida • Chicago, Illinois • Urbana, Illinois + 9 more
- Conditions
- Sleep, Sleep Disturbance, Sleep Disorder, Shift Work, Health Knowledge, Attitudes, Practice, Health Behavior, Fatigue, Vibration; Exposure
- Interventions
- Enhanced Cab, Fit4Sleep
- Other · Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Advanced Solid Tumors, Aggressive B-cell Lymphomas
- Interventions
- MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab, MEDI6469 plus Rituximab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate
- Drug · Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- DPX-Survivac, low dose cyclophosphamide (oral)
- Biological · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more
- Conditions
- Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
- Interventions
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Sylmar, California • Royal Oak, Michigan • Lima, Ohio
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Ketamine, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Nicky Mehtani, MD, MPH
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francicso, California